Search Results
Search for other papers by F McManus in
Google Scholar
PubMed
Search for other papers by R Fraser in
Google Scholar
PubMed
Search for other papers by E Davies in
Google Scholar
PubMed
Search for other papers by J M C Connell in
Google Scholar
PubMed
Search for other papers by E M Freel in
Google Scholar
PubMed
Introduction Corticosteroids are key regulators of the cardiovascular system. It has increasingly been accepted that aberrant blood pressure regulation and other cardiovascular consequences can be associated with altered production of the end
Search for other papers by Cynthia L Blanco in
Google Scholar
PubMed
Search for other papers by Alvaro G Moreira in
Google Scholar
PubMed
Search for other papers by Lisa L McGill-Vargas in
Google Scholar
PubMed
Search for other papers by Diana G Anzueto in
Google Scholar
PubMed
Search for other papers by Peter Nathanielsz in
Google Scholar
PubMed
Neonatology Division, Diabetes Division, Geriatric Research, Barshop Institute for Longevity and Aging Studies, Department of Obstetrics, Department of Pediatrics
Neonatology Division, Diabetes Division, Geriatric Research, Barshop Institute for Longevity and Aging Studies, Department of Obstetrics, Department of Pediatrics
Search for other papers by Nicolas Musi in
Google Scholar
PubMed
Introduction Antenatal corticosteroid administration to pregnant women has become the standard of care for mothers at a risk of delivering a premature infant. Maternal treatment with synthetic glucocorticoids (GCs) decreases the incidence of many
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
Search for other papers by Marian Joëls in
Google Scholar
PubMed
Variation in brain exposure to corticosteroid hormones Humans or rodents that are exposed to potentially threatening situations (i.e. stressors, subjectively experienced as ‘stress’) are able to trigger a hormonal response that promotes
Search for other papers by IM Adcock in
Google Scholar
PubMed
Search for other papers by SJ Lane in
Google Scholar
PubMed
Corticosteroids are the most potent anti-inflammatory agents used to treat chronic inflammatory diseases such as bronchial asthma. However, there are a small number (<5%) of asthmatic patients who do not respond well, or at all, to corticosteroid therapy - the corticosteroid-resistant and corticosteroid-dependent patients. Although this phenomenon is relatively uncommon, it poses a difficult therapeutic problem because few alternative therapies are available and these patients account for >50% of the health care costs of asthma. If the mechanisms for corticosteroid insensitivity are understood they may, in turn, provide insight into the key mechanism of corticosteroid action and allow a rational way to treat these individuals whose disease tends to be severe. Corticosteroid insensitivity is not limited to asthma and is a feature of other inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease. Thus, elucidation of the cause for the relative lack of corticosteroid response in this subgroup of asthmatic individuals may have important implications for other diseases.
Search for other papers by Femke L Groeneweg in
Google Scholar
PubMed
Search for other papers by Henk Karst in
Google Scholar
PubMed
Search for other papers by E Ron de Kloet in
Google Scholar
PubMed
Search for other papers by Marian Joëls in
Google Scholar
PubMed
players and phases involved in the stress response and their interactions with each other. Corticosteroids play a major role in the response of the brain to stress. For many years, they were believed to be only responsible for the delayed and prolonged
Hudson Institute of Medical Research, Clayton, Australia
Search for other papers by Morag J Young in
Google Scholar
PubMed
Search for other papers by Colin D Clyne in
Google Scholar
PubMed
Search for other papers by Karen E Chapman in
Google Scholar
PubMed
cellular phenotype, another potential modifier of disease. Glucocorticoid receptor, corticosteroids and COVID-19 Given their powerful anti-inflammatory and immunomodulatory effects, corticosteroids are an obvious potential therapy for ALI/ARDS in
Search for other papers by Gavin P Vinson in
Google Scholar
PubMed
Introduction Pick up any endocrinology text published in the last 60 years, and if it deals with the actions of the corticosteroids, you will usually read something to the effect that deoxycorticosterone (DOC, 11-deoxycorticosterone, cortexone, 21
Search for other papers by Lesley A Hill in
Google Scholar
PubMed
Search for other papers by Dimitra A Vassiliadi in
Google Scholar
PubMed
Search for other papers by Ioanna Dimopoulou in
Google Scholar
PubMed
Search for other papers by Anna J Anderson in
Google Scholar
PubMed
Search for other papers by Luke D Boyle in
Google Scholar
PubMed
Search for other papers by Alixe H M Kilgour in
Google Scholar
PubMed
Search for other papers by Roland H Stimson in
Google Scholar
PubMed
Search for other papers by Yoan Machado in
Google Scholar
PubMed
Search for other papers by Christopher M Overall in
Google Scholar
PubMed
Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Search for other papers by Brian R Walker in
Google Scholar
PubMed
Search for other papers by John G Lewis in
Google Scholar
PubMed
Search for other papers by Geoffrey L Hammond in
Google Scholar
PubMed
Introduction Corticosteroid-binding globulin (CBG) transports glucocorticoids and progesterone in human blood and regulates their access to target tissues ( Hammond 2016 a ). Human CBG is also known as SERPINA6 because it shares structural
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada
Search for other papers by Lesley A Hill in
Google Scholar
PubMed
Search for other papers by Tamara S Bodnar in
Google Scholar
PubMed
Search for other papers by Joanne Weinberg in
Google Scholar
PubMed
Department of Obstetrics and Gynaecology, University of British Columbia, Vancouver, British Columbia, Canada
Search for other papers by Geoffrey L Hammond in
Google Scholar
PubMed
Introduction Produced primarily by the liver, corticosteroid-binding globulin (CBG) is a plasma glycoprotein that binds ~90% of circulating glucocorticoids, and regulates their bioavailability in target tissues ( Lin et al. 2010 ). Plasma
Search for other papers by Gabriele E Mattos in
Google Scholar
PubMed
Search for other papers by Jan-Michael Heinzmann in
Google Scholar
PubMed
Search for other papers by Stefanie Norkowski in
Google Scholar
PubMed
Max Planck Institute of Psychiatry, Institut National de la Recherche Agronomique (INRA), University of Bordeaux, Research Group of Psychoneuroendocrinology, Kraepelinstrasse 2-10, 80804 Munich, Germany
Search for other papers by Jean-Christophe Helbling in
Google Scholar
PubMed
Max Planck Institute of Psychiatry, Institut National de la Recherche Agronomique (INRA), University of Bordeaux, Research Group of Psychoneuroendocrinology, Kraepelinstrasse 2-10, 80804 Munich, Germany
Search for other papers by Amandine M Minni in
Google Scholar
PubMed
Max Planck Institute of Psychiatry, Institut National de la Recherche Agronomique (INRA), University of Bordeaux, Research Group of Psychoneuroendocrinology, Kraepelinstrasse 2-10, 80804 Munich, Germany
Search for other papers by Marie-Pierre Moisan in
Google Scholar
PubMed
Search for other papers by Chadi Touma in
Google Scholar
PubMed
, sex hormone-, and corticosteroid-binding globulin (CBG, also called transcortin). CBG is a monomeric glycoprotein synthesized and stored mainly by the liver ( Rothschild et al . 1972 , Weiser et al . 1979 , Kuhn et al . 1986 , Hammond et al
